Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 1
An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worl…
Non Small Cell Lung Carcinoma
Estimated
~$10 – $7,500
AbbVieNCT06772623
Phase 1
Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Sur…
Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small Cell LungNon-Small Cell Lung Carcinoma+2 more
Estimated
~$10 – $5,625
National Cancer Institute (NCI)NCT06694454
Quality Improvement Study of a New Generation of Whole Body PET Scanners
The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn …
Non Small Cell Lung Carcinoma NSCLCHead and Neck CancerProstate Cancer
Estimated
~$10 – $750
Memorial Sloan Kettering Cancer CenterNCT07690917
Phase 1
PRISM: Phase 1b of Retifanlimab and Ruxolitinib In Solid Malignancies Progressing on Prior Checkpoint Inhibition
The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carc…
Non Small Cell Lung CarcinomaRenal Cell Carcinoma
Estimated
~$10 – $6,250
University of California, San DiegoNCT07219576